Celltrion eyes biosim Remicade launch in the U.S. this year

Celltrion marketing CEO Stanley Hong has set his sights on shipping a less expensive version of rheumatoid arthritis drug Remicade to the U.S. in the third quarter, pending approval from the FDA. It could become the second big threat to a U.S. biologic blockbuster, after Novartis ($NVS) won approval for its Neupogen biosim last month. In February, the U.S. Patent Office rejected a patent that would have protected Remicade until 2018. Report

Suggested Articles

With a potential approval next year in the up-and-coming NASH field, Intercept is staffing up its sales team and starting talks with payers.

Mavenclad helped Merck KGaA's neuroscience portfolio grow 2.3% in the third quarter, even in the face of Rebif's 15% year-over-year sales decline.

After showing Nucala could cut the rates of flares for hypereosinophilic syndrome, GSK is planning regulatory filings in 2020.